Impact of Gleason score on biochemical recurrence free survival after radical prostatectomy with positive surgical margins

Purpose. - Research of predictive factors of biochemical recurrence to guide the establishment of an adjuvant treatment after radical prostatectomy for cancer with positive surgical margins. Methodology. - A retrospective cohort of 1577 afro-caribbean patients undergoing radical prostatectomy operated between 1st January 2000 and 1st July 2013 was analyzed. In this cohort, 406 patients had positive surgical margin, we excluded 11 patients who received adjuvant therapy (radiotherapy, hormonotherapy, radio-hormonotherapy) and 2 patients for whom histological analysis of the surgical specimen was for a pT4 pathological stage. After a descriptive analysis, we used a Cox model to took for predictors of survival without biochemical recurrence then, depending on the significant variables, we separated our population into six groups: stage pT2 with Gleason score <= 3 + 4 (group 1), stage pT2 with a score of Gleason >= 4 + 3 (group 2), stage pT3a with a Gleason core <= 3 + 4 (group 3), pT3a stage with a score of Gleason >= 4 + 3 (group 4), stage pT3b with a Gleason score <= 3 + 4 (group 5) and stage pT3b Gleason >= with a score of 4 + 3 (group 6) and compared survival without biochemical recurrence using a log rank test. After radical prostatectomy with surgical margins with an anatomopathological stage <= pT3b, a Gleason score >= 4 + 3 had a pejorative survival without biochemical recurrence than pathological stage (P < 0.001). Results. - In multivariate analysis, predictors of survival without biochemical recurrence after radical prostatectomy with positive surgical margins were the majority Gleason postoperative (P < 0.0001), pathological stage (P = 0.049) adjusted preoperative PSA (P = 0.826), with the body mass index (BMI) (P = 0.59) and tumor volume (P = 0.95). Conclusion. - A high postoperatively Gleason score (>= 4+3) has a better predictive value of biochemical recurrence than pathological stage pT2 or pT3 at the patients having been treated for prostate cancer by radical prostatectomy with positive surgical margins. (C) 2017 Elsevier Masson SAS. All rights reserved.